计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
利菲拉非尼（BGB-283）, 丝氨酸/苏氨酸蛋白激酶 B-raf 抑制剂
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Information
Lifirafenib (BGB-283, Beigene-283) potently inhibitsRAFfamily kinases andEGFRactivities in biochemical assays withIC50values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
In vitro
In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification. In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. It demonstrates selective cytotoxicity to cell lines harboring BRAFV600E or EGFR mutations. BGB-283 inhibits the EGF-induced EGFR autophosphorylation on Tyr1068 in A431 cells in a dose-dependent manner. In WiDr colorectal cancer cells, BGB-283 is shown to be able to inhibit the feedback activation of EGFR signaling and achieves sustained inhibition of pERK.
In vivo
In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation. BGB-283 is highly efficacious in BRAF(V600E) colorectal cancer xenograft models, including HT29, Colo205, and two primary tumor xenografts harboring BRAFV600E mutation. In addition, BGB-283 shows compelling efficacy in a WiDr xenograft model where EGFR reactivation is shown to be induced upon BRAF inhibition. BGB-283 induces tumor regression in HCC827 but not in A431 xenograft. BGB-283 inhibits phosphorylation of both ERK1/2 and EGFR and displays potent antitumor activity in WiDr tumor xenografts. BGB-283 does not induce EGFR feedback activation as reported for vemurafenib. BGB-283 potently inhibits MEK and ERK phosphorylation and DUSP6 expression in vivo when dosed repeatedly. There is no detectable difference on AKT phosphorylation.
Cell Data
cell lines：
Concentrations：0.03, 1, 10 μM
Incubation Time：3 days
Powder Purity:≥99%
规格
英文别名
Beigene-283 | 1,8-Naphthyridin-2(1H)-one, 5-[[1a,6b-dihydro-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-cyclopropa[b]benzofuran-5-yl]oxy]-3,4-dihydro-
规格或纯度
Moligand™, 10mM in DMSO
英文名称
Lifirafenib (BGB-283)
生化机理
利非非尼（BGB-283，Beigene-283）在生化试验中能有效抑制 RAF 家族激酶和表皮生长因子受体的活性，对重组 BRAFV600E 激酶域、表皮生长因子受体和表皮生长因子受体 T790M/L858R 突变体的 IC50 值分别为 23、29 和 495 nM。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
丝氨酸/苏氨酸蛋白激酶 B-raf 抑制剂
名称和识别符
分子类型
小分子
Isomeric SMILES
C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F
分子量
478.42
Reaxy-Rn
23782872
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23782872&ln=
技术文档
高级数据
产品属性
| IC50 | EGFR, IC50: 29 nM |
|---|
关联靶点（人）
EGFR
Tclin
表皮生长因子受体(Epidermal growth factor receptor)
(1 活性数据)
BRAF
Tclin
丝氨酸/苏氨酸蛋白激酶B-raf(Serine/threonine-protein kinase B-raf)
(1 活性数据)
ARAF
Tchem
丝氨酸/苏氨酸蛋白激酶 A-Raf(Serine/threonine-protein kinase A-Raf)
(1 活性数据)
化学和物理性质
溶解性
Solubility (25°C) In vitro Water: 52 mg/mL (201.73 mM); Ethanol: 52 mg/mL (201.73 mM); DMSO: Insoluble;
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）